Moderna Inc at Barclays Global Healthcare Conference Transcript

Mar 12, 2024 / 06:35PM GMT
Huidong Wang - Barclays Bank PLC, Research Division - Research Analyst

Welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover SMID-cap biotech. It is my great pleasure to introduce our next presenting company, Moderna. With us today, we have Lavina Talukdar, SVP, Head of Investor Relations.

Questions and Answers:

Huidong Wang - Barclays Bank PLC, Research Division - Research Analyst

So Lavina, I think we don't need to have an overview. Everyone knows Moderna's very well. I will start with COVID revenue regarding 2024 guidance. You do give a guidance of a $4 billion total revenue. And within that, you have, say, $1 billion is from COVID APA and the $2-plus billion in U.S. revenue and additional $1 billion is ex-U.S. COVID-plus -- sorry, the RSV and the international COVID, right? So maybe starting with APA, how confident we are with this $1 billion that will be executed in 2024?

Lavina Talukdar - Moderna, Inc. - Senior VP & Head of IR

Well, thank you, Gena, for having us. I'm
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot